What is Avalo Therapeutics's restricted cash?

Avalo Therapeutics (AVTX) reported restricted cash of $147K in Q1 2026.

How has Avalo Therapeutics's restricted cash changed year-over-year?

Avalo Therapeutics's restricted cash increased by 137.1% year-over-year, from $62K to $147K.

What is the long-term trend for Avalo Therapeutics's restricted cash?

Over 5 years (2020 to 2025), Avalo Therapeutics's restricted cash has grown at a -0.5% compound annual growth rate (CAGR), from $38K to $37K.

What does restricted cash mean?

Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

Avalo Therapeutics AVTX Restricted Cash

Restricted Cash at other companies

XencorXNCR

$191K-32.7%

AbCellera Biologics Inc.ABCL

$25M0.0%

Absci CorporationABSI

$1.06M-93.4%

ImmunomeIMNM

$210K+110%

Arcus BiosciencesRCUS

$3M0.0%

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

See full

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

See full

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

See full

Market cap$946.18M+1,783%

Enterprise value$921.19M-1,342%

P/S1,892.4×+1,852×

Profitability

See full

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

See full

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avalo Therapeutics's restricted cash?: Avalo Therapeutics (AVTX) reported restricted cash of $147K in Q1 2026.
How has Avalo Therapeutics's restricted cash changed year-over-year?: Avalo Therapeutics's restricted cash increased by 137.1% year-over-year, from $62K to $147K.
What is the long-term trend for Avalo Therapeutics's restricted cash?: Over 5 years (2020 to 2025), Avalo Therapeutics's restricted cash has grown at a -0.5% compound annual growth rate (CAGR), from $38K to $37K.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.